Aleksey G Kazantsev

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease
    Aleksey G Kazantsev
    Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Bldg 114, 3300 16th St, Charlestown, MA 02129 4404, USA
    Arch Neurol 65:1577-81. 2008
  2. doi request reprint Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
    Aleksey G Kazantsev
    Harvard Medical School, Massachusetts General Hospital, Mass General Institute for Neurodegenerative Disease, Charlestown, Massachusetts 02129 4404, USA
    Nat Rev Drug Discov 7:854-68. 2008
  3. ncbi request reprint Cellular pathways leading to neuronal dysfunction and degeneration
    Aleksey G Kazantsev
    Department of Neurology, Harvard Medical School, Disease, Massachusetts, USA
    Drug News Perspect 20:501-9. 2007
  4. pmc Drug targeting of dysregulated transcription in Huntington's disease
    Aleksey G Kazantsev
    Harvard Medical School, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129 4404, USA
    Prog Neurobiol 83:249-59. 2007
  5. ncbi request reprint Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA
    Science 317:516-9. 2007
  6. pmc The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models
    Vanita Chopra
    Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129 4404, USA
    Cell Rep 2:1492-7. 2012
  7. pmc The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS
    Michele M Maxwell
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02115, USA
    Hum Mol Genet 20:3986-96. 2011
  8. ncbi request reprint Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models
    Tiago Fleming Outeiro
    Department of Neurology, Harvard Medical School and MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg 114 3300, 16th St, Charlestown, MA 02129 4404, USA
    Biochem Biophys Res Commun 357:596-602. 2007
  9. ncbi request reprint Two approaches to drug discovery in SOD1-mediated ALS
    Wendy J Broom
    Day Neuromuscular Research Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129, USA
    J Biomol Screen 11:729-35. 2006
  10. ncbi request reprint Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells
    Stephen M Altmann
    Massachusetts General Institute for Neurodegenerative Disease and Harvard Medical School, Department of Neurology, Massachusetts General Hospital, Charlestown, 02129, USA
    Chem Biol 13:765-70. 2006

Collaborators

Detail Information

Publications16

  1. doi request reprint Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease
    Aleksey G Kazantsev
    Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Bldg 114, 3300 16th St, Charlestown, MA 02129 4404, USA
    Arch Neurol 65:1577-81. 2008
    ..Herein, we review the data supporting this concept, propose a scheme of events leading to synuclein-induced neuronal death, and discuss protein deacetylase sirtuins as new potential therapeutic targets involved in this process...
  2. doi request reprint Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
    Aleksey G Kazantsev
    Harvard Medical School, Massachusetts General Hospital, Mass General Institute for Neurodegenerative Disease, Charlestown, Massachusetts 02129 4404, USA
    Nat Rev Drug Discov 7:854-68. 2008
    ....
  3. ncbi request reprint Cellular pathways leading to neuronal dysfunction and degeneration
    Aleksey G Kazantsev
    Department of Neurology, Harvard Medical School, Disease, Massachusetts, USA
    Drug News Perspect 20:501-9. 2007
    ..Elucidation of the precise neurodegenerative mechanism(s) is essential for development of effective and safe therapy for these lethal human disorders...
  4. pmc Drug targeting of dysregulated transcription in Huntington's disease
    Aleksey G Kazantsev
    Harvard Medical School, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129 4404, USA
    Prog Neurobiol 83:249-59. 2007
    ..In this chapter we review current progress in this area of therapeutic development. We also discuss possible drug discovery strategies targeting altered transcriptional pathways...
  5. ncbi request reprint Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA
    Science 317:516-9. 2007
    ..Furthermore, the inhibitors protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease. The results suggest a link between neurodegeneration and aging...
  6. pmc The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models
    Vanita Chopra
    Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129 4404, USA
    Cell Rep 2:1492-7. 2012
    ..Our results provide preclinical validation of SIRT2 inhibition as a potential therapeutic target for HD and support the further development of SIRT2 inhibitors for testing in humans...
  7. pmc The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS
    Michele M Maxwell
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02115, USA
    Hum Mol Genet 20:3986-96. 2011
    ....
  8. ncbi request reprint Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models
    Tiago Fleming Outeiro
    Department of Neurology, Harvard Medical School and MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg 114 3300, 16th St, Charlestown, MA 02129 4404, USA
    Biochem Biophys Res Commun 357:596-602. 2007
    ..Further, our results suggest a rationale for the development of highly potent, bio-available, brain-penetrable PARP-1 inhibitors to provide therapeutic benefits for Parkinson's patients...
  9. ncbi request reprint Two approaches to drug discovery in SOD1-mediated ALS
    Wendy J Broom
    Day Neuromuscular Research Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129, USA
    J Biomol Screen 11:729-35. 2006
    ..Ultimately, the authors believe that these 2 cell-based assays will provide powerful strategies to identify novel therapies for the treatment of inherited SOD1-associated forms of ALS...
  10. ncbi request reprint Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells
    Stephen M Altmann
    Massachusetts General Institute for Neurodegenerative Disease and Harvard Medical School, Department of Neurology, Massachusetts General Hospital, Charlestown, 02129, USA
    Chem Biol 13:765-70. 2006
    ..The protective role of PARP1 inhibitors against oxidative stress has been shown in this model system...
  11. pmc RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells
    Michele M Maxwell
    Day Laboratory for Neuromuscular Research and High Throughput Screening Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 101:3178-83. 2004
    ..The present study further supports the therapeutic potential of RNAi-based methods for the treatment of inherited human diseases, including ALS...
  12. ncbi request reprint Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments
    Myra Coufal
    Massachusetts Institute of Technology, Cambridge, MA, USA
    J Biomol Screen 12:351-60. 2007
    ..These compounds were subjected to a functional assay, which yielded a lead compound that rescues cells from induced mutant polyglutamine toxicity...
  13. ncbi request reprint Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators
    Dorotea Rigamonti
    Centre for Stem Cell Research and Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, Milan 20133, Italy
    J Biol Chem 282:24554-62. 2007
    ....
  14. pmc Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases
    Ruth A Bodner
    Center for Cancer Research, Massachusetts Institute of Technology, Room E18 505, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 103:4246-51. 2006
    ....
  15. pmc A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo
    Xiaoqian Zhang
    Department of Biochemistry, Boston University Medical School, Boston, MA 02118, USA
    Proc Natl Acad Sci U S A 102:892-7. 2005
    ..The aggregation inhibitors identified in this screen represent four primary chemical scaffolds and are strong lead compounds for the development of therapeutics for human polyQ diseases...
  16. ncbi request reprint New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions
    Ruth A Bodner
    Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Cell Cycle 5:1477-80. 2006
    ..In this review, we discuss these results, and place them in the context of ongoing therapeutic discovery efforts for Huntington's disease and other neurodegenerative diseases...